Print

Purpose

This study is designed to evaluate the relative bioavailability (rBA) of multiple test tablet formulations of BMS-986435 compared to an equal dose of the BMS-986435 reference tablet formulation. The effect of food on the drug levels of selected BMS-986435 tablet formulations will also be evaluated.

Condition

Eligibility

Eligible Ages
Between 18 Years and 60 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Participants must have a body weight of ≥ 45 kg and BMI between 18 and 32 kg/m2, inclusive - Participants must be healthy as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), clinical laboratory assessments - Participants must have documented left ventricular ejection fraction (LVEF) ≥ 60% and absence of significant cardiac abnormality at screening, as determined by local transthoracic echocardiogram (TTE) assessment - Other protocol-defined Inclusion/

Exclusion Criteria

apply

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Treatment A
  • Drug: BMS-986435
    Specified dose on specified days
    Other names:
    • MYK-224
Experimental
Treatment B
  • Drug: BMS-986435
    Specified dose on specified days
    Other names:
    • MYK-224
Experimental
Treatment C
  • Drug: BMS-986435
    Specified dose on specified days
    Other names:
    • MYK-224
Experimental
Treatment D
  • Drug: BMS-986435
    Specified dose on specified days
    Other names:
    • MYK-224
Experimental
Treatment E
  • Drug: BMS-986435
    Specified dose on specified days
    Other names:
    • MYK-224
Experimental
Treatment F
  • Drug: BMS-986435
    Specified dose on specified days
    Other names:
    • MYK-224
Experimental
Treatment G
  • Drug: BMS-986435
    Specified dose on specified days
    Other names:
    • MYK-224
Experimental
Treatment H
  • Drug: BMS-986435
    Specified dose on specified days
    Other names:
    • MYK-224
Experimental
Treatment I
  • Drug: BMS-986435
    Specified dose on specified days
    Other names:
    • MYK-224
Experimental
Treatment J
  • Drug: BMS-986435
    Specified dose on specified days
    Other names:
    • MYK-224
Experimental
Treatment K
  • Drug: BMS-986435
    Specified dose on specified days
    Other names:
    • MYK-224
Experimental
Treatment L
  • Drug: BMS-986435
    Specified dose on specified days
    Other names:
    • MYK-224

Recruiting Locations

Quotient Miami
Miami, Florida 33126
Contact:
Juliet Vento, Site 0001

More Details

Status
Recruiting
Sponsor
Bristol-Myers Squibb

Study Contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
855-907-3286
Clinical.Trials@bms.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.